Alofisel▼ (darvadstrocel) Shows Clinical Remission Ra

18.02.2022 - Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission* was observed in 65% of patients in both cohorts who were evaluated at 6 months.1 INSPIRE is a European, observational, ...

Related Keywords

Alofi , Niue General , Niue , Japan , United States , United Kingdom , Israel , Switzerland , Tel Aviv , Israeli , Elisabeth Genestin , Van Assche , Oded Zmora , Injektion Darvadstrocelum , Ann Gastroenterol , Takeda Pharmaceuticals United States Inc , Admire Cd Study Group Collaborators , Senior Global Brand Medical Affairs , Takeda Pharmaceutical Company Ltd , Takeda Pharmaceutical Company , European Union Economic Area , European Union , Takeda Pharmaceutical Company Limited , Japan Pharmaceuticals , European Network Of Centres , Department Of Surgery , Ministry Of Health Israel , Exchange Commission , Shamir Medical Center , Devices Agency , Bradshaw Index , Professor Oded Zmora , Rectal Surgeon , Shamir Medical , Senior Global Brand Medical Affairs Director , Regenerative Medicine Advanced Therapy , European Economic Area , Product Characteristics , Rare Genetics , Plasma Derived Therapies , Pharmaceutical Company Limited , Annual Report , European Network , Medical Devices , Products Approved , Regenerative Medical , Israeli Drug , Pharmaceutical Company , Pharmaceuticals United States , Drug Evaluation , Takeda Logo , Takeda Yakuhin Kogyo ,